| Stereochemistry | ABSOLUTE |
| Molecular Formula | C37H49N7O9S |
| Molecular Weight | 767.891 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC3=CC=CC=C3)C(N)=O
InChI
InChIKey=NEYNJQRKHLUJRU-DZUOILHNSA-N
InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1
| Molecular Formula | C37H49N7O9S |
| Molecular Weight | 767.891 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Pentagastrin (trade name Peptavlon) is a cholecystokinin type B (CCK(B)) receptor agonist, which was indicated as a diagnostic aid for evaluation of gastric acid secretory function. It was effective in testing for an acidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It was effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Pentagastrin was also indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor. Peptavlon was discontinued, Federal Register determined that product was not discontinued or withdrawn for safety or efficacy reasons. In addition was shown, that Pentagastrin may release adrenocorticotropin (ACTH) and cortisol through direct pharmacological action, perhaps enhanced on first exposure by psychologically mediated novelty effects. Novelty, per se, is not likely the primary mediator of the hypothalamic-pituitary-adrenal (HPA) response. This model may be useful for further study of cognitive-emotional modulators of HPA axis activity.
Approval Year
PubMed
Sample Use Guides
The intravenous infusion dose has ranged from 0.1 to 12 ug (0.0001 to 0.012 mg) per kg of body weight per hour administered in a 0.9% sodium chloride injection.
As a subcutaneous injection for gastric function study with a dose of 6 ug (0.006 mg) per kg of body weight.
Route of Administration:
Other
The centrifugal spreading of multicellular aggregates from a DMH induced colon adenocarcinoma cell line from rats was observed in vitro. Various concentrations of pentagastrin were added to the culture medium. Using 10 micrograms/ml of pentagastrin, the migration idex and the area covered by the cells were increased (P less than 0.01) while the cell density was not. Inhibition of cell division through addition of 5 fluoro-uracil to the culture medium abolished the stimulating effect of pentagastrin although the centrifugal migration was not suppressed by the antimetabolite. These data indicate that a supraphysiological concentration of pentagastrin can stimulate the spreading of colon cancer cell aggregates in vitro by enhanced proliferation.
